^
    Apply
    Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (NRG-LU003) (NCT03737994)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    07/25/2019
    Primary completion :
    07/21/2021
    Completion :
    09/21/2024
    MET
    |
    ALK positive • MET amplification • ALK rearrangement
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)
    Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PIKACHU) (NCT04322890)
    Phase 2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/16/2020
    Primary completion :
    12/24/2026
    Completion :
    12/24/2027
    EGFR • BRAF • ALK • ROS1
    |
    EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation
    |
    cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)
    PF-07284892 in Participants With Advanced Solid Tumors (NCT04800822)
    Phase 1
    Pfizer
    Active, not recruiting
    Last update posted :
    04/30/2024
    Initiation :
    03/17/2021
    Primary completion :
    06/18/2024
    Completion :
    11/29/2025
    ALK • ROS1 • NF1
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive
    |
    Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892
    Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (NCT03126916)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    04/22/2024
    Initiation :
    05/14/2018
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    MYCN
    |
    MYCN amplification
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane
    Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients (NCT04979988)
    Phase N/A
    Pfizer
    Completed
    Last update posted :
    04/05/2024
    Initiation :
    08/02/2021
    Primary completion :
    12/09/2021
    Completion :
    12/09/2021
    ALK
    |
    ALK rearrangement
    |
    Alecensa (alectinib) • Lorbrena (lorlatinib)
    Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer (NCT04362072)
    Phase 4
    Pfizer
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    09/29/2020
    Primary completion :
    06/25/2024
    Completion :
    06/25/2024
    ALK
    |
    ALK rearrangement
    |
    Lorbrena (lorlatinib)
    Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE) (NCT04111705)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Active, not recruiting
    Last update posted :
    03/07/2024
    Initiation :
    08/05/2020
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    ALK
    |
    ALK rearrangement
    |
    Lorbrena (lorlatinib)
    A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled (NCT06282991)
    Phase N/A
    Pfizer
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    07/22/2020
    Primary completion :
    01/18/2021
    Completion :
    01/18/2021
    ALK
    |
    Lorbrena (lorlatinib)
    A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China (NCT03909971)
    Phase 2
    Pfizer
    Active, not recruiting
    Last update posted :
    02/21/2024
    Initiation :
    04/28/2019
    Primary completion :
    08/10/2020
    Completion :
    12/31/2024
    EML4
    |
    ALK positive • EML4-ALK fusion • ALK fusion
    |
    Lorbrena (lorlatinib)
    A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC (CROWN) (NCT03052608)
    Phase 3
    Pfizer
    Active, not recruiting
    Last update posted :
    02/20/2024
    Initiation :
    04/27/2017
    Primary completion :
    03/20/2020
    Completion :
    12/31/2028
    ALK
    |
    ALK positive
    |
    Xalkori (crizotinib) • Lorbrena (lorlatinib)
    Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (ALKALINE) (NCT04127110)
    Phase 2
    European Organisation for Research and Treatmen...
    Active, not recruiting
    Last update posted :
    02/16/2024
    Initiation :
    11/17/2020
    Primary completion :
    07/01/2024
    Completion :
    11/01/2024
    ALK
    |
    ALK rearrangement
    |
    Lorbrena (lorlatinib)
    Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project) (GALILEO) (NCT06234579)
    Phase N/A
    Fondazione Policlinico Universitario Agostino G...
    Recruiting
    Last update posted :
    01/31/2024
    Initiation :
    07/12/2021
    Primary completion :
    03/31/2024
    Completion :
    07/31/2026
    ALK
    |
    Alecensa (alectinib) • Lorbrena (lorlatinib) • Alunbrig (brigatinib)
    Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) (NCT04621188)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Recruiting
    Last update posted :
    12/19/2023
    Initiation :
    03/19/2021
    Primary completion :
    03/01/2025
    Completion :
    01/01/2026
    ROS1
    |
    ROS1 rearrangement
    |
    Lorbrena (lorlatinib)
    Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC (NCT06092086)
    Phase 2
    Guangdong Association of Clinical Trials
    Recruiting
    Last update posted :
    10/20/2023
    Initiation :
    08/18/2023
    Primary completion :
    08/01/2025
    Completion :
    08/01/2030
    ALK
    |
    ALK positive • ALK rearrangement • ALK mutation
    |
    Lorbrena (lorlatinib)
    A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer (NCT06007937)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    08/23/2023
    Initiation :
    08/17/2023
    Primary completion :
    08/17/2028
    Completion :
    08/17/2028
    ALK
    |
    ALK fusion
    |
    Lorbrena (lorlatinib) • Cyramza (ramucirumab)
    A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (CRU3) (NCT03505554)
    Phase 2
    University of Milano Bicocca
    Recruiting
    Last update posted :
    08/07/2023
    Initiation :
    10/10/2017
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    ALK
    |
    Lorbrena (lorlatinib)
    A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations (NCT01970865)
    Phase 1/2
    Pfizer
    Completed
    Last update posted :
    06/07/2023
    Initiation :
    01/08/2014
    Primary completion :
    03/15/2017
    Completion :
    05/24/2023
    ALK
    |
    ALK positive • ALK rearrangement • ALK mutation • ROS1 positive • ROS1 rearrangement
    |
    Xalkori (crizotinib) • Lorbrena (lorlatinib)
    Post Marketing Surveillance(PMS) Study of Lorviqua in Korea (NCT05599412)
    Phase N/A
    Pfizer
    Recruiting
    Last update posted :
    06/06/2023
    Initiation :
    05/22/2023
    Primary completion :
    08/10/2028
    Completion :
    08/10/2028
    ALK
    |
    ALK positive
    |
    Lorbrena (lorlatinib)
    Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease (NCT04541407)
    Phase 1
    University of Colorado, Denver
    Completed
    Last update posted :
    05/16/2023
    Initiation :
    10/29/2020
    Primary completion :
    04/25/2022
    Completion :
    06/07/2022
    ALK
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L858R + EGFR exon 21 deletion
    |
    Tagrisso (osimertinib) • temozolomide • Lorbrena (lorlatinib)
    Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment (LORLAPULM) (NCT05167500)
    Phase N/A
    Fundación GECP
    Completed
    Last update posted :
    03/30/2023
    Initiation :
    12/09/2021
    Primary completion :
    12/30/2022
    Completion :
    12/30/2022
    ALK • ROS1
    |
    Lorbrena (lorlatinib)
    Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India (NCT04541706)
    Phase 4
    Pfizer
    Completed
    Last update posted :
    09/14/2022
    Initiation :
    08/27/2020
    Primary completion :
    07/20/2022
    Completion :
    07/20/2022
    ALK
    |
    ALK rearrangement
    |
    Lorbrena (lorlatinib)
    Study of Lorlatinib in ROS1 Rearranged NSCLC (NCT03612154)
    Phase 2
    National Cancer Center, Korea
    Recruiting
    Last update posted :
    04/06/2022
    Initiation :
    05/02/2019
    Primary completion :
    12/31/2022
    Completion :
    12/31/2023
    ROS1
    |
    ROS1 rearrangement
    |
    Lorbrena (lorlatinib)
    PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer (PFROST) (NCT03439215)
    Phase 2
    Fondazione Ricerca Traslazionale
    Active, not recruiting
    Last update posted :
    07/19/2021
    Initiation :
    06/13/2017
    Primary completion :
    06/01/2022
    Completion :
    06/01/2022
    ROS1
    |
    ROS1 rearrangement
    |
    Xalkori (crizotinib) • Lorbrena (lorlatinib)
    Lorlatinib Combinations in Lung Cancer (NCT04292119)
    Phase 1/2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    03/10/2021
    Initiation :
    05/01/2020
    Primary completion :
    12/01/2022
    Completion :
    03/01/2023
    ALK • ROS1
    |
    ALK rearrangement • ROS1 positive • ROS1 rearrangement
    |
    Xalkori (crizotinib) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • batoprotafib (TNO155)
    Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive (NCT03178071)
    Phase N/A
    Pfizer
    No Longer Available
    Last update posted :
    11/04/2019
    ALK
    |
    ALK positive • ALK rearrangement • ROS1 positive • ROS1 rearrangement • ALK G1202R
    |
    Lorbrena (lorlatinib)